← Leaderboards
Kieren J Mather
Indiana Univ-Purdue Univ At Indianapolis
$8,113,774
Attributed
$9,816,365
Total exposure
25
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–18$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$9,816,365 · 25
By mechanism
U01$4,529,518 · 2
R01$3,405,183 · 1
R21$832,154 · 2
P30$477,999 · 1
M01$293,902 · 18
R37$277,609 · 1
Top collaborators
- Johnathan D Tune6 shared
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- Helmut O Steinberg$131,165
- Lang Li$13,579,025
- Alain D Baron$796,609
- Rose S Fife$6,386,774
- Tamara S Hannon$4,645,857
Others in their field
Top investigators on “Diabetes Mellitus”
- Jeffrey P Krischer · University Of South Florida$608,226,434
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$177,347,135
- John M Lachin · George Washington University$155,262,668
- David M Nathan · Massachusetts Institute Of Technology$142,806,023
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Jose A Luchsinger · Columbia University Health Sciences$75,551,718
Research focus
Diabetes MellitusObesityGlucoseResponseMetabolicNon-Insulin-Dependent Diabetes MellitusInsulinMeasurementCostPreventRandomizedInsulin ResistanceAttenuatedRestHyperglycemiaDiabetes PreventionPrediabetes SyndromeResearch PersonnelGlycosylated Hemoglobin APrevalenceLifestyle InterventionMetforminHealth EconomicsCohort
Grant awards (47)
14/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 â Research Project$348,830
U01 · FY2018 · DK · contact PI
Translation Core$117,000
P30 · FY2018 · DK · contact PI
Cardiovascular effects of GLP-1 in obesity/metabolic syndrome$660,047
R01 · FY2017 · HL
14/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 â Research Project$386,148
U01 · FY2017 · DK · contact PI
Translation Core$117,000
P30 · FY2017 · DK · contact PI
Cardiovascular effects of GLP-1 in obesity/metabolic syndrome$663,167
R01 · FY2016 · HL
14/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 â Research Project$351,000
U01 · FY2016 · DK · contact PI
Translation Core$117,000
P30 · FY2016 · DK · contact PI
14/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 â Research Project$45,240
U01 · FY2016 · DK · contact PI
14/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 â Research Project$30,852
U01 · FY2016 · DK · contact PI
Cardiovascular effects of GLP-1 in obesity/metabolic syndrome$662,933
R01 · FY2015 · HL
Preservation of Beta Cell Function in Prediabetes Early Type 2 Diabetes$155,491
U01 · FY2015 · DK · contact PI
Translation Core$126,999
P30 · FY2015 · DK · contact PI
Cardiovascular effects of GLP-1 in obesity/metabolic syndrome$709,525
R01 · FY2014 · HL
Preservation of Beta Cell Function in Prediabetes Early Type 2 Diabetes$550,413
U01 · FY2014 · DK · contact PI
Preservation of Beta Cell Function in Prediabetes Early Type 2 Diabetes$144,188
U01 · FY2014 · DK · contact PI
Cardiovascular effects of GLP-1 in obesity/metabolic syndrome$678,907
R01 · FY2013 · HL
Preservation of Beta Cell Function in Prediabetes Early Type 2 Diabetes$590,151
U01 · FY2013 · DK · contact PI
Preservation of Beta Cell Function in Prediabetes Early Type 2 Diabetes$262,710
U01 · FY2013 · DK · contact PI
Cardiovascular effects of GLP-1 in obesity/metabolic syndrome$30,604
R01 · FY2013 · HL
Preservation of Beta Cell Function in Prediabetes Early Type 2 Diabetes$551,931
U01 · FY2012 · DK · contact PI
Preservation of Beta Cell Function in Prediabetes Early Type 2 Diabetes$311,946
U01 · FY2012 · DK · contact PI
Preservation of Beta Cell Function in Prediabetes Early Type 2 Diabetes$755,513
U01 · FY2011 · DK · contact PI
Modulation of Human Myocardial Metabolism by GLP-1$192,500
R21 · FY2011 · HL · contact PI
Preservation of Beta Cell Function in Prediabetes/Early Type 2 Diabetes$45,105
U01 · FY2011 · DK · contact PI
Modulation of Human Myocardial Metabolism by GLP-1$231,000
R21 · FY2010 · HL · contact PI
DUAL ACTIONS OF INSULIN IN THE REGULATION OF ENDOTHELIN ACTIVITY IN VIVO IN H$2,530
M01 · FY2008 · RR · contact PI
MYOCARDIAL SUBSTRATE SELECTION AND SWITCHING IN LEAN AND OBESE HUMANS$858
M01 · FY2008 · RR · contact PI
TREATING THE ENDOTHELIUM TO RESTORE INSULIN SENSITIVITY$494
M01 · FY2008 · RR · contact PI
MECHANISM OF HEMODYNAMICALLY INDUCED GLUCOSE UPTAKE$247
M01 · FY2008 · RR · contact PI
REPAGLINIDE AS A VIABLE ALTERNATIVE TO PRE-MEAL INSULIN IN CYSTIC FIBROSIS RE$87
M01 · FY2008 · RR · contact PI
DUAL ACTIONS OF INSULIN IN THE REGULATION OF ENDOTHELIN ACTIVITY IN VIVO IN H$29,777
M01 · FY2007 · RR · contact PI
MYOCARDIAL SUBSTRATE SELECTION AND SWITCHING IN LEAN AND OBESE HUMANS$10,097
M01 · FY2007 · RR · contact PI
TREATING THE ENDOTHELIUM TO RESTORE INSULIN SENSITIVITY$5,817
M01 · FY2007 · RR · contact PI
MECHANISM OF HEMODYNAMICALLY INDUCED GLUCOSE UPTAKE$2,908
M01 · FY2007 · RR · contact PI
REPAGLINIDE AS A VIABLE ALTERNATIVE TO PRE-MEAL INSULIN IN CYSTIC FIBROSIS RE$1,027
M01 · FY2007 · RR · contact PI
PET Approach To Measuring Human Myocardial Metabolism$181,404
R21 · FY2006 · DK · contact PI
DUAL ACTIONS OF INSULIN IN THE REGULATION OF ENDOTHELIN ACTIVITY IN VIVO IN H$26,867
M01 · FY2006 · RR · contact PI
TREATING THE ENDOTHELIUM TO RESTORE INSULIN SENSITIVITY$16,363
M01 · FY2006 · RR · contact PI
MECHANISM OF HEMODYNAMICALLY INDUCED GLUCOSE UPTAKE$10,101
M01 · FY2006 · RR · contact PI
THE EFFECTS OF OLMESARTAN MEDOXOMIL, LOSARTAN POTASSIUM, AND ATENOLOL ON INSU$202
M01 · FY2006 · RR · contact PI
PET Approach To Measuring Human Myocardial Metabolism$227,250
R21 · FY2005 · DK
MECHANISM OF HEMODYNAMICALLY INDUCED GLUCOSE UPTAKE$41,307
M01 · FY2005 · RR
TREATING THE ENDOTHELIUM TO RESTORE INSULIN SENSITIVITY$10,161
M01 · FY2005 · RR
THE EFFECTS OF OLMESARTAN MEDOXOMIL, LOSARTAN POTASSIUM, AND ATENOLOL ON INSU$1,988
M01 · FY2005 · RR
Mechanism of Hemodynamically Induced Glucose Uptake$133,071
M01 · FY2004 · RR
ROLE OF HEMODYNAMICS IN IN VIVO INSULIN RESISTANCE$277,609
R37 · FY2003 · DK